IL150755A0 - Uses of agonists and antagonists to modulate activity of tnf-related molecules - Google Patents

Uses of agonists and antagonists to modulate activity of tnf-related molecules

Info

Publication number
IL150755A0
IL150755A0 IL15075500A IL15075500A IL150755A0 IL 150755 A0 IL150755 A0 IL 150755A0 IL 15075500 A IL15075500 A IL 15075500A IL 15075500 A IL15075500 A IL 15075500A IL 150755 A0 IL150755 A0 IL 150755A0
Authority
IL
Israel
Prior art keywords
methods
tnf
agonists
modulate activity
antagonists
Prior art date
Application number
IL15075500A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL150755A0 publication Critical patent/IL150755A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
IL15075500A 2000-02-16 2000-11-28 Uses of agonists and antagonists to modulate activity of tnf-related molecules IL150755A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18293800P 2000-02-16 2000-02-16
US22698600P 2000-08-22 2000-08-22
PCT/US2000/032378 WO2001060397A1 (en) 2000-02-16 2000-11-28 Uses of agonists and antagonists to modulate activity of tnf-related molecules

Publications (1)

Publication Number Publication Date
IL150755A0 true IL150755A0 (en) 2003-02-12

Family

ID=26878566

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15075500A IL150755A0 (en) 2000-02-16 2000-11-28 Uses of agonists and antagonists to modulate activity of tnf-related molecules

Country Status (14)

Country Link
US (1) US20060073146A1 (xx)
EP (2) EP1255558B1 (xx)
JP (1) JP5062606B2 (xx)
AT (2) ATE511857T1 (xx)
AU (1) AU2048501A (xx)
CA (1) CA2396793A1 (xx)
CY (1) CY1105212T1 (xx)
DE (1) DE60028830T2 (xx)
DK (2) DK1255558T3 (xx)
ES (1) ES2267593T3 (xx)
HK (1) HK1093674A1 (xx)
IL (1) IL150755A0 (xx)
PT (1) PT1255558E (xx)
WO (1) WO2001060397A1 (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EE05673B1 (et) † 1999-08-17 2013-08-15 Biogen, Inc. BAFF-retseptor (BCMA), immunoregulatoorne agens
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
MXPA02011130A (es) * 2000-05-12 2003-03-10 Amgen Inc Metodos y composiciones de materia que se refieren a april/g70, bcma, blys/agp-3, y taci.
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
NZ522700A (en) * 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP2301971A1 (en) * 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
RS20120253A1 (xx) 2001-05-24 2013-02-28 Zymogenetics Inc. Taci-imunoglobulinski fuzioni proteini
US7189820B2 (en) 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
AU2002330074A1 (en) 2001-09-21 2003-04-01 Amgen Inc. Tall-1 receptor molecules and uses thereof
WO2003041730A1 (en) * 2001-11-16 2003-05-22 Genset S.A. Ditacin agonists and antagonists for use in the treatment of metabolic disorders
EP1456347A4 (en) * 2001-11-16 2006-08-02 Human Genome Sciences Inc ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
CN1692127A (zh) * 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
DE60329116D1 (de) * 2002-10-11 2009-10-15 Zymogenetics Inc Herstellung von homotrimeren fusionsproteinen
PT2272868E (pt) * 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
WO2006067210A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
MX2008014365A (es) 2006-05-15 2008-11-27 Ares Trading Sa Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
WO2008119042A2 (en) * 2007-03-27 2008-10-02 Zymogenetics, Inc. Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
WO2009062926A1 (en) * 2007-11-12 2009-05-22 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
JP2011503035A (ja) * 2007-11-12 2011-01-27 アレス トレーディング ソシエテ アノニム 視神経炎治療のためのｔａｃｉ−免疫グロブリン融合タンパク質
EP2219675B1 (en) 2007-11-12 2013-10-23 Ares Trading S.A. Formulations for taci-immunoglobulin fusion proteins
AU2015201974B2 (en) * 2009-03-02 2016-12-15 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (APRIL)
EP2403528B1 (en) 2009-03-02 2016-04-20 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (april)
JP6061469B2 (ja) 2009-03-10 2017-01-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗ｂｃｍａ抗体
WO2011047121A1 (en) * 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
EP2971077B1 (en) 2013-03-15 2019-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
EP3243831A1 (en) * 2014-02-27 2017-11-15 Ucl Business Plc Variants of the proliferation-inducing ligand (april)
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
DK3380522T3 (da) 2015-11-25 2024-01-22 Visterra Inc Antistofmolekyler til april og anvendelser deraf
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
CN116903727A (zh) 2020-05-08 2023-10-20 高山免疫科学股份有限公司 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法
WO2022131889A1 (ko) * 2020-12-16 2022-06-23 주식회사 굳티셀 Taci 단백질의 용도

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5182196A (en) * 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
DE68926679T2 (de) * 1988-09-22 1996-10-17 Teijin Ltd Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5587457A (en) * 1990-03-12 1996-12-24 Peptide Technology Limited Neutrophil stimulating peptides
US5519119A (en) * 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
SK376492A3 (en) * 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69326937T2 (de) 1993-03-24 2000-12-28 Berlex Biosciences Richmond Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
KR960011859B1 (ko) * 1993-04-22 1996-09-03 현대전자산업 주식회사 반도체 소자의 필드 산화막 형성방법
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
WO1997033902A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
ATE302272T1 (de) 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CN1624128A (zh) 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
IL132304A0 (en) 1997-04-16 2001-03-19 Amgen Inc Osteoprotegerin binding proteins and receptors
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
WO1999007738A2 (en) 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
CA2301202A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2303615A1 (en) * 1997-09-12 1999-03-18 Jurg Tschopp April- a novel protein with growth effects
HUP0004034A3 (en) 1997-09-12 2002-08-28 Apotech R & D Sa Kay - a novel immune system protein
WO1999050416A1 (en) 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
US6297022B1 (en) * 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
WO1999019490A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6355782B1 (en) * 1998-07-09 2002-03-12 Baylor College Of Medicine Hypohidrotic ectodermal dyplasia genes and proteins
MY136203A (en) * 1998-08-11 2008-08-29 Idec Pharma Corp Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
CZ299819B6 (cs) * 1999-01-25 2008-12-03 Biogen Idec Ma Inc. Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
AU4986700A (en) * 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
ES2331644T3 (es) * 1999-06-09 2010-01-12 Immunomedics, Inc. Inmunoterapia de trastornos autoinmunes usando anticuerpos cuya diana son celulas b.
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
EE05673B1 (et) * 1999-08-17 2013-08-15 Biogen, Inc. BAFF-retseptor (BCMA), immunoregulatoorne agens
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
MXPA02004599A (es) * 1999-11-08 2002-10-23 Idec Pharma Corp Tratamiento de tumores malignos de celula b utilizando anticuerpos anti-cd40l en combinacion con anticuerpos anti-cd20 y/o agentes quimioterapeuticos y radioterapia.
AU2001234953B2 (en) * 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
WO2001072333A1 (en) * 2000-03-24 2001-10-04 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
AU5914201A (en) * 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
MXPA02011130A (es) * 2000-05-12 2003-03-10 Amgen Inc Metodos y composiciones de materia que se refieren a april/g70, bcma, blys/agp-3, y taci.
AU7013401A (en) * 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
DE60140773D1 (de) * 2000-08-18 2010-01-21 Dyax Corp Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
US20030092164A1 (en) * 2000-11-07 2003-05-15 Gross Jane A. Human tumor necrosis factor receptor
IL156618A0 (en) * 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
EP2301971A1 (en) * 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
ATE507839T1 (de) * 2001-04-02 2011-05-15 Genentech Inc Kombinationstherapie
CN1636067A (zh) * 2001-08-03 2005-07-06 杰南技术公司 TACls和BR3多肽及其用途
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
AU2002330074A1 (en) * 2001-09-21 2003-04-01 Amgen Inc. Tall-1 receptor molecules and uses thereof
EP1443961B1 (en) * 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US7150003B2 (en) * 2002-11-25 2006-12-12 Matsushita Electric Industrial Co., Ltd. Class coalescence for obfuscation of object-oriented software

Also Published As

Publication number Publication date
US20060073146A1 (en) 2006-04-06
WO2001060397A1 (en) 2001-08-23
CY1105212T1 (el) 2010-03-03
EP1255558B1 (en) 2006-06-14
JP5062606B2 (ja) 2012-10-31
DE60028830T2 (de) 2007-01-18
DE60028830D1 (de) 2006-07-27
JP2003522800A (ja) 2003-07-29
WO2001060397A9 (en) 2002-12-05
DK1255558T3 (da) 2006-10-23
ES2267593T3 (es) 2007-03-16
AU2048501A (en) 2001-08-27
EP1666052B1 (en) 2011-06-08
EP1255558A1 (en) 2002-11-13
ATE329610T1 (de) 2006-07-15
ATE511857T1 (de) 2011-06-15
EP1666052A1 (en) 2006-06-07
DK1666052T3 (da) 2011-09-12
CA2396793A1 (en) 2001-08-23
PT1255558E (pt) 2006-11-30
HK1093674A1 (en) 2007-03-09

Similar Documents

Publication Publication Date Title
IL150755A0 (en) Uses of agonists and antagonists to modulate activity of tnf-related molecules
MXPA04001050A (es) Polipeptidos tacis y br3 y usos de los mismos.
YU83600A (sh) Adenozin a3 receptorski modulatori
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2003012067A3 (en) Expression profile of prostate cancer
Deshayes et al. Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
MX2010006739A (es) Compuestos pirido[2,3-b]pirazina-8-sustituidos y su uso.
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
EP2481814A3 (en) Compositions and methods for treating and diagnosing cancer
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
EP2363480A3 (en) Modulation of glucocorticoid receptor expression
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
WO2006014678A3 (en) Compositions and methods of using angiopoietin-like 4 protein
WO2008063202A3 (en) Heterobicyclic thiophene compounds for the treatment of cancer
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
WO2005000088A3 (en) Expression profile of pancreatic cancer
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
AU8881201A (en) Tnf receptor-like molecules and uses thereof
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser